Literature DB >> 26516317

Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.

Mara Balda1, Maria Calvó2, Eduardo Padilla3, Gonzalo Guerrero4, Juan Molina5, Nestor V Florenzano6, Danielle Kamis5, Javier I Escobar7, C Robert Cloninger8, Gabriel de Erausquin5.   

Abstract

Schizophrenia is a debilitating psychiatric illness that is among the world's top 10 causes of long-term disability, affecting people who are just entering the peak of social, economic, and intellectual productivity. Such functional loss is particularly relevant in indigenous communities, which rely on change in functional status (rather than on the presence of symptoms) to identify mental illness. Particularly among the indigenous communities of Latin America, the gap between mental health need and availability of resources to reduce the burden has been judged "a case of outrageous exclusion." For more than a decade, as part of the Investigation of Movement Abnormalities and Genetic of Schizophrenia study, the authors have been studying vulnerability markers (genetic, motor, imaging, and neuropsychological differences) for schizophrenia in a remote, indigenous population in rural northern Argentina. In this article, the authors discuss the implementation of a task-shifting paradigm resulting in more proficient identification and referral of individuals with untreated psychosis and a severalfold reduction in the duration of untreated psychosis, with very high retention rates (70%) and treatment adherence during a decade in a rural environment. The authors also propose to use transcranial ultrasound screening and testing for parkinsonism at illness onset before introduction of neuroleptics as potentially useful markers in determining illness severity, negative symptomatology, and tolerance to antipsychotic treatment/refractoriness.

Entities:  

Year:  2015        PMID: 26516317      PMCID: PMC4621078          DOI: 10.1176/appi.focus.20150018

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  53 in total

Review 1.  A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.

Authors:  Marianne Klemp; Ingunn Fride Tvete; Tor Skomedal; Jørund Gaasemyr; Bent Natvig; Ivar Aursnes
Journal:  J Clin Psychopharmacol       Date:  2011-12       Impact factor: 3.153

2.  The clinical global impressions scale: applying a research tool in clinical practice.

Authors:  Joan Busner; Steven D Targum
Journal:  Psychiatry (Edgmont)       Date:  2007-07

3.  The efficacy of targeted health agents education to reduce the duration of untreated psychosis in a rural population.

Authors:  Eduardo Padilla; Juan Molina; Danielle Kamis; Maria Calvo; Lee Stratton; Sergio Strejilevich; Gabriela Gonzalez Aleman; Gonzalo Guerrero; Mercedes Bourdieu; Horacio A Conesa; Javier I Escobar; Gabriel A de Erausquin
Journal:  Schizophr Res       Date:  2014-11-28       Impact factor: 4.939

4.  Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.

Authors:  K Wahlbeck; M Cheine; A Essali; C Adams
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

5.  Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.

Authors:  M H Chakos; D I Mayerhoff; A D Loebel; J M Alvir; J A Lieberman
Journal:  Psychopharmacol Bull       Date:  1992

6.  Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.

Authors:  Nancy C Andreasen; Marcus Pressler; Peg Nopoulos; Del Miller; Beng-Choon Ho
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

7.  Susceptibility to neuroleptic-induced parkinsonism--age and increased substantia nigra echogenicity as putative risk factors.

Authors:  Burkhard Emanuel Jabs; Andreas Joachim Bartsch; Bruno Pfuhlmann
Journal:  Eur Psychiatry       Date:  2003-06       Impact factor: 5.361

Review 8.  Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology.

Authors:  Rajiv Tandon; Matcheri S Keshavan; Henry A Nasrallah
Journal:  Schizophr Res       Date:  2008-06-02       Impact factor: 4.939

9.  Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz
Journal:  J Neurol       Date:  2012-08-05       Impact factor: 4.849

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  2 in total

1.  Prediction of Neurocognitive Deficits by Parkinsonian Motor Impairment in Schizophrenia: A Study in Neuroleptic-Naïve Subjects, Unaffected First-Degree Relatives and Healthy Controls From an Indigenous Population.

Authors:  Juan L Molina; Gabriela González Alemán; Néstor Florenzano; Eduardo Padilla; María Calvó; Gonzalo Guerrero; Danielle Kamis; Lee Stratton; Juan Toranzo; Beatriz Molina Rangeon; Helena Hernández Cuervo; Mercedes Bourdieu; Manuel Sedó; Sergio Strejilevich; Claude Robert Cloninger; Javier I Escobar; Gabriel A de Erausquin
Journal:  Schizophr Bull       Date:  2016-03-18       Impact factor: 9.306

2.  Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia.

Authors:  Juan L Molina; María Calvó; Eduardo Padilla; Mara Balda; Gabriela González Alemán; Néstor V Florenzano; Gonzalo Guerrero; Danielle Kamis; Beatriz Molina Rangeon; Mercedes Bourdieu; Sergio A Strejilevich; Horacio A Conesa; Javier I Escobar; Igor Zwir; C Robert Cloninger; Gabriel A de Erausquin
Journal:  NPJ Schizophr       Date:  2017-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.